Remedy Cell Announces Initiation of Phase 1b Clinical Trial of RC-0315 in IPF Patients
Haifa, Israel — Remedy Cell, a clinical-stage biopharmaceutical company focused on the development of proprietary cell-derived therapies for fibrotic diseases, today announces the initiation of “A partially-blinded randomized Phase 1b single and repeat dose (4-cohort) safety & tolerability study of RC-0315/Placebo administered intra-bronchially to idiopathic pulmonary fibrosis patients”. The primary objective of the RC-0315 First-in-Human, Phase…
Pluri and Remedy Cell Expand Collaboration; Successful Engineering Runs and Clinical-Grade Manufacturing Achieved
HAIFA, Israel, Dec. 22, 2025 (GLOBE NEWSWIRE) — Pluri, Inc. (“Pluri”, the “Company”, “we” or “us”) (Nasdaq, TASE: PLUR), a leading biotechnology company leveraging its proprietary platform for cell-based solutions through a collaborative network of ventures, today announced expansion of its manufacturing agreement signed in 2024 with Remedy Cell Ltd. (“Remedy Cell”), an innovative biopharmaceutical…
Qureight and Remedy Cell partner to integrate deep learning platform into Phase 1b study of RC-0315 in IPF
Qureight Ltd, a Core Imaging Laboratory with deep-learning analytics, and Remedy Cell, a clinical-stage biopharmaceutical company focused on the development of proprietary cell-derived therapies for fibrotic diseases, have partnered to validate RC-0315’s mechanism of action in idiopathic pulmonary fibrosis (IPF). The primary objective of the RC-0315 Phase 1b clinical study is to measure drug safety…
PluriCDMO partners with Remedy Cell for IPF treatment production
HAIFA, Israel – Pluri Inc. (NASDAQ:PLUR) (TASE:PLUR), a biotechnology firm specializing in cell-based solutions, has entered a manufacturing agreement with Remedy Cell Ltd. Through its contract development and manufacturing organization (COMO) division, PluriCDMO™,the company will produce clinical-grade materials for Remedy Cell’s RC- 0315, a drug candidate aimed at treating Idiopathic Pulmonary Fibrosis (IPF). Remedy Cell,…